Figure 1 | Scientific Reports

Figure 1

From: Both p62/SQSTM1-HDAC6-dependent autophagy and the aggresome pathway mediate CDK1 degradation in human breast cancer

Figure 1

DNA-damaging agents and proteasome inhibitors induce CDK1 degradation via the lysosomal pathway. Exponentially growing MCF7 (A) and MCF10A (B) cells were treated with the indicated agents and extracts were transferred and immunoblotted with the indicated antibodies. (C): extract without any treatment. Dx: doxorubicin; Eto: etoposide; 5-Fu: 5-fluorouracil; Oxa: oxaliplatin; CP: cyclophosphamide. Graphs show quantification of CDK1 protein levels using ImageJ software. (C) MCF7 and MCF10A cells were treated with or without the proteasome inhibitor MG132 at the indicated time points. Western blots were performed on lysates using the indicated antibodies. (D) MCF7, MCF10A, MDA-MB231, HCT116, HEK293T, and hTERT RPE1 cells were treated or not with trehalose for 24 hours, and samples analyzed by immunoblots. (E) MCF7 cells were pretreated with concanamycin A (Con A) or bafilomycin A1 (Baf A1) for 30 min, and then treated with MG132 (4 hours) or etoposide (Eto, 24 hours). Lysates were analyzed by Western blot. (F) MCF7 cells were pretreated with cycloheximide (CHX, 30 min) and treated as in (E).

Back to article page